Current treatment status-Not currently treated Posts on Medivizor
Navigation Menu

Current treatment status-Not currently treated Posts on Medivizor

MTX-HOPE chemotherapy for patients over 70 with relapsed non-Hodgkin’s lymphoma

MTX-HOPE chemotherapy for patients over 70 with relapsed non-Hodgkin’s lymphoma

Posted by on Jun 27, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, etoposide) to treat patients over 70 with non-Hodgkin’s lymphoma (NHL) which had returned after previous treatments. It found that MTX-HOPE was an effective and safe treatment for these patients. Some background NHL is a group of cancers of the...

Read More

Differentiation syndrome in patients of IDH-mutated acute myeloid leukemia treated with ivosidenib and enasidenib

Differentiation syndrome in patients of IDH-mutated acute myeloid leukemia treated with ivosidenib and enasidenib

Posted by on Jun 7, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the occurrence of differentiation syndrome (DS) in patients with IDH-mutated acute myeloid leukemia (AML) under ivosidenib (Tibsovo) and enasidenib (Idhifa) therapy. The authors found that DS is a common and adverse condition in such patients. Some background Mutations or changes in the isocitrate dehydrogenase (IDH)...

Read More

Managing patients with chronic myeloid leukemia who fail responding to second generation tyrosine kinase inhibitors

Managing patients with chronic myeloid leukemia who fail responding to second generation tyrosine kinase inhibitors

Posted by on Jun 7, 2020 in Leukemia | 0 comments

In a nutshell The report recommends how to manage patients with chronic-phase chronic myeloid leukemia (CP-CML) who failed to respond to 2nd generation tyrosine kinase inhibitors (TKIs). The authors suggested to consider patient-specific factors and personalize treatment for such patients. Some background TKIs deactivate cancerous enzymes which cause...

Read More

Which low-intensity chemotherapy is most effective for patients with classical Hodgkin lymphoma receiving stem cell transplantation?

Posted by on May 10, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the effectiveness of three low-intensity chemotherapy combinations to treat patients with classical Hodgkin lymphoma (HL) following stem cell transplantation (SCT). There were no significant differences between the three chemotherapy types in terms of patients’ survival and relapse. Some background...

Read More

Have the outcomes of stem cell transplants for young patients with relapsed or refractory Hodgkin lymphoma improved over time?

Posted by on Apr 25, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if the outcomes of stem cell transplants (SCT) have improved for young patients with relapsed or refractory Hodgkin lymphoma (HL) over time. The results showed that SCT has improved the survival rate and reduced the relapse rate of HL in young patients in recent years. Some background While initial treatment is...

Read More

Hemopoietic stem cell transplant after chimeric antigen receptor T-cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia

Posted by on Apr 25, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if a hemopoietic stem cell transplant should be carried out after chimeric antigen receptor T cell therapy in patients with B-cell acute lymphoblastic leukemia.   This study concluded that this treatment path led to high event-free survival in these patients.   Some background...

Read More

How effective is BV-DHAP chemotherapy to treat patients with relapsed or refractory Hodgkin lymphoma?

Posted by on Apr 25, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined the effectiveness and safety of the chemotherapy combination BV-DHAP for patients with relapsed or refractory Hodgkin lymphoma (HL). The authors found that BV-DHAP was an effective and safe treatment to progress patients to high-dose chemotherapy and stem cell transplant. Some background During treatment, some...

Read More

Evaluating brentuximab vedotin for elderly patients with hard to treat Hodgkin lymphoma

Posted by on Mar 24, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) in elderly patients with relapsed or unresponsive Hodgkin lymphoma (HL). This study found that this treatment was effective, although frail patients may be at higher risk for side effects. Some background Most patients with HL respond to front-line...

Read More

Evaluating brentuximab vedotin plus bendamustine for patients with hard-to-treat classical Hodgkin lymphoma

Posted by on Mar 8, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of brentuximab vedotin (Adcetris) plus bendamustine (Treanda) for patients with hard to treat classical Hodgkin lymphoma (cHL). This study found that this regimen is an effective salvage therapy for these patients. Some background Standard first-line chemotherapy is highly effective in treating...

Read More

Evaluating high-dose cyclophosphamide for patients with hard-to-treat B-cell non-Hodgkin’s lymphoma

Posted by on Jan 12, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of high-dose cyclophosphamide (Cytoxan) for the treatment of relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that high-dose cyclophosphamide was safe and effective for these patients. Some background Chemotherapy regimens remain a standard treatment...

Read More